TABLE OF CONTENTS
1 INTRODUCTION 66
1.1 OBJECTIVES OF THE STUDY 66
1.2 MARKET DEFINITION 66
1.3 OVERVIEW OF THE ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET 66
1.4 CURRENCY AND PRICING 68
1.5 LIMITATIONS 68
1.6 MARKETS COVERED 68
2 MARKET SEGMENTATION 73
2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 DBMR TRIPOD DATA VALIDATION MODEL 76
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79
2.6 MULTIVARIATE MODELLING 80
2.7 TEST TYPE SEGMENT LIFELINE CURVE 80
2.8 MARKET END USER COVERAGE GRID 81
2.9 DBMR MARKET POSITION GRID 82
2.10 VENDOR SHARE ANALYSIS 83
2.11 SECONDARY SOURCES 84
2.12 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 88
4.1 PESTEL ANALYSIS 89
4.2 PORTER'S FIVE FORCES MODEL 90
5 INDUSTRY INSIGHTS 91
6 NUMBER OF LABS 93
6.1 NUMBER OF LABS IN MIDDLE EASTERN COUNTRIES 93
6.2 NUMBER OF LABS IN EUROPE 93
7 REGULATIONS OF THE ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET 95
7.1 SINGAPORE 96
7.2 CHINA 96
8 MARKET OVERVIEW 98
8.1 DRIVERS 100
8.1.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 100
8.1.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS 100
8.1.3 GROWING PREVALENCE OF CHRONIC DISEASES 100
8.1.4 INCREASING AWARENESS AND ACCEPTANCE TOWARDS THE ASSISTANCES OF LDTS 101
8.2 RESTRAINTS 101
8.2.1 STRINGENT QUALITY CONTROL AND STANDARDIZATION FOR LDTS 101
8.2.2 STRICT REGULATORY GUIDELINES REGARDING LDTS 102
8.3 OPPORTUNITIES 102
8.3.1 INCREASING DEMAND FOR PRECISION MEDICINE AND TARGETED THERAPY 102
8.3.2 ENHANCED HEALTHCARE SUBSTRUCTURE 103
8.4 CHALLENGES 103
8.4.1 DEPRIVED DATA INTERPRETATION AND INTEGRATION 103
8.4.2 COMPLEX LABORATORY PROCESSES 104
9 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE 105
9.1 OVERVIEW 106
9.2 CLINICAL CHEMISTRY AND IMMUNOLOGY 109
9.2.1 GLUCOSE 110
9.2.1.1 GLUCOSE CHALLENGE TEST 110
9.2.1.2 ORAL GLUCOSE TOLERANCE TEST (OGTT) 110
9.2.2 PROTHROMBIN 111
9.2.3 METABOLIC PANEL 111
9.2.3.1 BASIC 111
9.2.3.2 COMPREHENSIVE 111
9.2.4 LIPID PANEL 111
9.2.5 LIVER PANEL 111
9.2.5.1 ALP TEST (ALKALINE PHOSPHATE) 112
9.2.5.2 ALT TEST (ALKALINE TRANSMINASE) 112
9.2.5.3 AST TEST (ASPARTATE AMINOTRANSFERASE) 112
9.2.5.4 GAMMA-GLUTAMYL TRANSFERASE (GGT) TEST 112
9.2.6 THYROID STIMULATING HORMONE 112
9.2.7 URINALYSIS 112
9.2.7.1 RED BLOOD CELL URINE TEST 113
9.2.7.2 GLUCOSE URINE TEST 113
9.2.7.3 PROTEIN URINE TEST 113
9.2.7.4 URINE PH LEVEL 113
9.2.7.5 KETONES URINE TEST 113
9.2.7.6 BILIBURIN URINE TEST 113
9.2.7.7 URINE SPECIFIC GRAVITY TEST 114
9.2.8 OTHERS 114
9.3 CRITICAL CARE 114
9.3.1 CARBOXYHAEMOGLOBIN TEST 115
9.3.2 PH TEST 115
9.3.3 POTASSIUM TEST 115
9.3.4 SODIUM TEST 115
9.3.5 METHEMOGLOBIN TEST 115
9.3.6 LACTATE TEST 115
9.3.7 OTHERS 116
9.4 HAEMATOLOGY 116
9.4.1 COMPLETE BLOOD COUNT (CBC) 117
9.4.1.1 WHITE BLOOD CELL COUNT (WBC) 117
9.4.1.2 RED BLOOD CELL COUNT (RBC) 117
9.4.2 PLATELET COUNT 117
9.4.3 BLOOD PROTEIN TESTING 118
9.4.4 OTHERS 118
9.5 MOLECULAR DIAGNOSTIC 118
9.5.1 SAMPLE TYPE 119
9.5.1.1 BLOOD 119
9.5.1.2 URINE 119
9.5.1.3 TISSUE 119
9.5.1.4 CEREBROSPINAL FLUID (CSF) 119
9.5.1.5 OTHERS 119
9.5.2 THERAPEUTIC AREA 119
9.5.2.1 INFECTIONS 120
9.5.2.2 GENETIC DISORDERS 120
9.5.2.3 ONCOLOGY/CANCER 120
9.5.2.4 AUTOIMMUNE DISEASE 120
9.5.2.5 UROLOGY 120
9.5.2.6 GYNECOLOGY 120
9.5.2.7 OTHERS 120
9.5.3 TECHNOLOGY 121
9.5.3.1 POLYMERASE CHAIN REACTION (PCR) 121
9.5.3.2 NEXT-GENERATION SEQUENCING (NGS) 121
9.5.3.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 121
9.5.3.4 SANGER SEQUENCING 121
9.5.3.5 MICROARRAYS 121
9.5.3.6 MASS SPECTROMETRY 122
9.5.3.7 ISOTHERMAL AMPLIFICATION 122
9.5.4 END USER 122
9.5.4.1 HOSPITAL-BASED LABS 122
9.5.4.2 STAND-ALONE LABS 122
9.5.4.3 DIAGNOSTIC CHAINS 122
9.5.4.4 ACADEMIC INSTITUTES 123
9.5.4.5 CLINICAL RESEARCH ORGANIZATIONS 123
9.5.4.6 SPECIALTY DIAGNOSTIC CENTERS 123
9.5.4.7 OTHERS 123
9.6 MICROBIOLOGY 123
9.6.1 MICROSCOPY 124
9.6.2 CULTURE 124
9.6.3 ANTIMICROBIAL SUSCEPTIBILITY TEST 124
9.6.4 OTHERS 124
9.7 OTHER TEST 125
9.7.1 DRUGS OF ABUSE TESTING 126
9.7.2 HEPATITIS 126
9.7.3 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) 126
9.7.4 MALARIA 126
9.7.5 TUBERCULOSIS 126
9.7.6 HUMAN PAPILLOMAVIRUS (HPV) 126
9.7.7 OTHERS 127
10 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE 128
10.1 OVERVIEW 129
10.2 CONSUMABLES 132
10.2.1 PANELS 132
10.2.2 REAGENT AND KITS 133
10.2.3 OTHERS 133
10.3 ANALYZERS AND INSTRUMENTS 133
10.3.1 FULLY-AUTOMATED INSTRUMENTS 134
10.3.2 SEMI-AUTOMATED INSTRUMENTS 134
10.3.3 OTHERS 134
10.4 ACCESSORIES 134
11 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE 136
11.1 OVERVIEW 137
11.2 BLOOD 140
11.3 URINE 140
11.4 TISSUE 141
11.5 CEREBROSPINAL FLUID (CSF) 141
11.6 OTHERS 142
12 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA 144
12.1 OVERVIEW 145
12.2 INFECTIONS 148
12.2.1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 149
12.2.2 CLOSTRIDIUM DIFFICILE 149
12.2.3 VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 149
12.2.4 CARBAPENEM-RESISTANT BACTERIA 149
12.2.5 FLU 149
12.2.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) 150
12.2.7 CANDIDA 150
12.2.8 TUBERCULOSIS AND DRUG-RESISTANT TBA 150
12.2.9 MENINGITIS 150
12.2.10 GASTROINTESTINAL PANEL TESTING 150
12.2.11 CHLAMYDIA 150
12.2.12 GONORRHEA 150
12.2.13 HIV 150
12.2.14 HEPATITIS B 150
12.2.15 HEPATITIS C 150
12.2.16 OTHER INFECTIOUS DISEASES 150
12.3 GENETIC DISORDERS 151
12.3.1 NEW BORN SCREENING 151
12.3.2 PREDICTIVE AND PRESYMPTOMATIC TESTING 152
12.3.3 OTHER GENETIC TESTING 152
12.4 OCNOLOGY/CANCER 152
12.4.1 BREAST CANCER 153
12.4.2 PROSTATE CANCER 153
12.4.3 COLORECTAL CANCER 153
12.4.4 CERVICAL CANCER 153
12.4.5 KIDNEY CANCER 153
12.4.6 LIVER CANCER 153
12.4.7 BLOOD CANCER 153
12.4.8 LUNG CANCER 154
12.4.9 OTHER CANCER 154
12.5 AUTOIMMUNE DISEASE 154
12.6 UROLOGY 154
12.7 GYNECOLOGY 155
12.8 OTHERS 156
13 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER 157
13.1 OVERVIEW 158
13.2 MALE 161
13.3 FEMALE 161
14 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP 163
14.1 OVERVIEW 164
14.2 GERIATRICS 167
14.3 ADULT 167
14.4 PEDIATRICS 168
15 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER 169
15.1 OVERVIEW 170
15.2 HOSPITAL-BASED LABS 173
15.3 STAND ALONE LABS 173
15.4 DIAGNOSTIC CHAINS 174
15.5 ACADEMIC INSTITUTES 175
15.6 CLINICAL RESEARCH ORGANISTAION 175
15.7 SPECIALTY DIAGNOSTIC 176
15.8 OTHERS 177
16 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL 178
16.1 OVERVIEW 179
16.2 DIRECT TENDER 182
16.3 RETAIL SALES 182
16.4 THIRD PARTY DISTRIBUTORS 183
16.5 OTHERS 184
17 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION 185
17.1 ASIA PACIFIC 186
17.1.1 CHINA 200
17.1.2 JAPAN 209
17.1.3 INDIA 218
17.1.4 AUSTRALIA 227
17.1.5 SOUTH KOREA 236
17.1.6 INDONESIA 245
17.1.7 PHILIPPINES 254
17.1.8 THAILAND 263
17.1.9 MALAYSIA 272
17.1.10 SINGAPORE 281
17.1.11 REST OF ASIA-PACIFIC 290
18 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, COMPANY LANDSCAPE 291
18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 291
19 COMPANY PROFILES 292
19.1 F. HOFFMANN-LA ROCHE LTD. 292
19.1.1 COMPANY SNAPSHOT 292
19.1.2 REVENUE ANALYSIS 292
19.1.3 COMPANY SHARE ANALYSIS 293
19.1.4 PRODUCT PORTFOLIO 293
19.1.5 RECENT DEVELOPMENT 293
19.2 BIOMRIEUX 294
19.2.1 COMPANY SNAPSHOT 294
19.2.2 REVENUE ANALYSIS 294
19.2.3 COMPANY SHARE ANALYSIS 295
19.2.4 PRODUCT PORTFOLIO 295
19.2.5 RECENT DEVELOPMENTS 295
19.3 SYSMEX CORPORATION 296
19.3.1 COMPANY SNAPSHOT 296
19.3.2 REVENUE ANALYSIS 296
19.3.3 COMPANY SHARE ANALYSIS 297
19.3.4 PRODUCT PORTFOLIO 297
19.3.5 RECENT DEVELOPMENT 297
19.4 BIOMERICA. 298
19.4.1 COMPANY SNAPSHOT 298
19.4.2 REVENUE ANALYSIS 298
19.4.3 COMPANY SHARE ANALYSIS 299
19.4.4 PRODUCT PORTFOLIO 299
19.4.5 RECENT DEVELOPMENT 299

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.